Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVLO NASDAQ:NEXI NASDAQ:SMFL NASDAQ:VRPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$9K0.858,944 shs7,000 shsNEXINexImmune$0.00+100.0%$0.00$0.00▼$1.01N/A2.045,849 shs149 shsSMFLSmart for Life$0.01-16.7%$0.01$0.00▼$0.10$35K17.065,603 shs757 shsVRPXVirpax Pharmaceuticals$0.03$0.02$0.01▼$26.25$31K1.49156,335 shs18 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVLOEvelo Biosciences0.00%0.00%0.00%0.00%+400.00%NEXINexImmune0.00%-98.00%0.00%+100.00%-99.92%SMFLSmart for Life0.00%+300.00%-25.93%-60.53%-93.18%VRPXVirpax Pharmaceuticals0.00%+66.23%+126.13%-92.06%-99.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.00$9K0.858,944 shs7,000 shsNEXINexImmune$0.00+100.0%$0.00$0.00▼$1.01N/A2.045,849 shs149 shsSMFLSmart for Life$0.01-16.7%$0.01$0.00▼$0.10$35K17.065,603 shs757 shsVRPXVirpax Pharmaceuticals$0.03$0.02$0.01▼$26.25$31K1.49156,335 shs18 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVLOEvelo Biosciences0.00%0.00%0.00%0.00%+400.00%NEXINexImmune0.00%-98.00%0.00%+100.00%-99.92%SMFLSmart for Life0.00%+300.00%-25.93%-60.53%-93.18%VRPXVirpax Pharmaceuticals0.00%+66.23%+126.13%-92.06%-99.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVLOEvelo Biosciences 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ASMFLSmart for Life 0.00N/AN/AN/AVRPXVirpax Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ASMFLSmart for Life$11.11M0.00N/AN/A($17.10) per share0.00VRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A11/24/2025 (Estimated)NEXINexImmune-$32.34M-$18.54N/A∞N/AN/A-534.32%-213.72%N/ASMFLSmart for Life-$22.68MN/A0.00∞N/AN/AN/AN/AN/AVRPXVirpax Pharmaceuticals-$15.19MN/A0.00∞N/AN/A-1,554.34%-338.29%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVLOEvelo BiosciencesN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVLOEvelo BiosciencesN/AN/AN/ANEXINexImmuneN/A0.660.66SMFLSmart for LifeN/AN/AN/AVRPXVirpax PharmaceuticalsN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVLOEvelo Biosciences0.31%NEXINexImmune9.85%SMFLSmart for Life28.39%VRPXVirpax Pharmaceuticals32.23%Insider OwnershipCompanyInsider OwnershipEVLOEvelo Biosciences1.02%NEXINexImmune14.90%SMFLSmart for Life31.71%VRPXVirpax Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataNEXINexImmune701.40 million1.19 millionNot OptionableSMFLSmart for Life1107.09 million4.84 millionNot OptionableVRPXVirpax Pharmaceuticals71.24 million4.71 millionNot OptionableEVLO, VRPX, SMFL, and NEXI HeadlinesRecent News About These CompaniesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comVirpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comVirpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using METMarch 11, 2025 | msn.comVirpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology ConferenceMarch 11, 2025 | msn.comVirpax Looking to Use MET to Develop Intranasal COVID VaccineMarch 7, 2025 | businesswire.comAnalysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)March 6, 2025 | markets.businessinsider.comVirpax’s NES100 to be Presented at The Society of Toxicology by NCATSMarch 5, 2025 | finance.yahoo.comVirpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope TechnologyMarch 3, 2025 | msn.comVirpax lauds Nanomerics’ MET study with no severe side effectsMarch 1, 2025 | investing.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | finance.yahoo.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | businesswire.comVirpax Confirms Positive Results with US Army with Probudur™ for Combat Care StudyFebruary 13, 2025 | joplinglobe.comJVirpax Pharmaceuticals confirms results with U.S. Army with ProbudurFebruary 13, 2025 | markets.businessinsider.comVirpax reports positive study results for pain management drugFebruary 13, 2025 | msn.comVirpax Pharmaceuticals appoints new independent directorFebruary 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVLO, VRPX, SMFL, and NEXI Company DescriptionsEvelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 09:31 AM EasternEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.NexImmune NASDAQ:NEXI$0.0002 +0.00 (+100.00%) As of 09/26/2025 10:21 AM EasternNexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Smart for Life NASDAQ:SMFL$0.0050 0.00 (-16.67%) As of 03:10 PM EasternSmart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.Virpax Pharmaceuticals NASDAQ:VRPX$0.03 0.00 (0.00%) As of 09/26/2025Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? This ETF Weeds Out Small-Cap Underperformers Dividend ETF SCHD Draws Buyers as Fed Cuts Spark Rotation Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300 MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
